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Methaemoglobin is formed when the haem iron of deoxyhaemoglobin is oxidized from its
ferrous (Fe2+) to the ferric state (Fe3+) resulting in a haemoglobin molecule that is
structurally and functionally altered, which leads to tissue hypoxia and metabolic
acidosis. Classiﬁcations of methaemoglobinemia are based on clinical history, causative
agents, pattern of transmission and optical spectrum presentation of blood specimen and
level of erythrocyte NADH-methaemoglobin reductase activity. Two major types of
molecular/metabolic events leading to the presentation of methaemoglobinemia have
been identiﬁed. The majority of the chemically induced-methaemoglobinemias are
outcome of the presence of relatively high concentrations of oxidizing agents that
overwhelm protective cellular reductive capacity of NADH-methaemoglobin reductase
activity rather than inhibition of the enzyme. The control of physiologic levels of
methaemoglobin is intricately intertwined with glucose metabolism for the supply of
NADH and NADPH to provide electrons and protons for enzymatic reduction of
methaemoglobin in concert with auxiliary antioxidant systems. The management and
amelioration of methaemoglobinemia involves exchange transfusion and/or methylene
blue administration.1. Introduction
Concisely, methaemoglobin is formed when the haem iron of
deoxyhaemoglobin is oxidized from its ferrous (Fe2+) to the
ferric state (Fe3+)[1]. Methaemoglobin does not bind reversibly
with oxygen and the haemoglobin molecule is structurally and
functionally altered[2,3], thereby inducing tissue hypoxia and
metabolic acidosis[4]. Furthermore, methaemoglobin activates
endothelial cells by stimulation of interleukin-6, interleukin-8,
and E-selectin[5], which promotes the release of cytokines and
expression of adhesion molecules, and thereby intensiﬁes
tissue inﬂammatory response[6]. The present review highlighted
the etiology and recent research advances in understanding the
patho-toxicological concerns of methaemoglobinemia, which
are of relevance to the clinician, pharmacist or toxicologist.2. Evidence acquisition
Scientiﬁc search engines such as PubMed, Pubget, Medline,
EMBASE, Mendeley, Google Scholar, ScienceDirect and
SpringerLink were used to retrieve online publications from
1957 to 2015. Keywords such as ‘methaemoglobin’, ‘meth-
aemoglobinopathies’, ‘NADH-methaemoglobin reductase’, ‘ni-
trate toxicity’ were used to collate relevant articles. The results
were then cross-referenced to generate a total number of 84
references cited in this review article.
3. Methaemoglobinemia
Under normal physiologic condition, methaemoglobin is
continually formed in erythrocytes[7,8]. However, the
concentration of methaemoglobin is usually kept between
1.0% and 3.0% in plasma[7,9–12], which implies that erythrocyte
must possess efﬁcient system to maintain low levels of
methaemoglobin. Case study reports showed that the onset of
toxic methaemoglobinemia is usually within 20–60 min
following exposure of the blood system to the causative
agent[13]. Mild clinically recognizable symptoms are present in
individuals whose plasma methaemoglobin concentration
exceeds 10%–15%, whereas plasma methaemoglobinlicense (http://
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fatigue, lightheadedness and nausea[9,13,14]. Dyspnoea on
exertion, lethargy and tachycardia occur at plasma
methaemoglobin concentration between 30% and 50%
followed by arrhythmias, tachycardia, coma, seizures,
respiratory distress and lactate acidosis at plasma
methaemoglobin concentration > 70%[13]. Further increase in
plasma methaemoglobin concentration causes cardiovascular
collapse and mortality may ensue if left untreated[9,15,16].
Methaemoglobinemia describes abnormally high plasma
concentration of haemoglobin in the Fe3+ state, which interferes
with the accuracy of pulse oximetry and arterial blood gas in-
dex[9,15,17]. Nevertheless, co-oximetry presents the most accurate
and reliable method for measurement of blood methaemoglobin
concentration[18]. Cyanosis devoid of respiratory distress is often
the earliest clinical evidence of methaemoglobinemia, in which
the patient is unresponsive to standard oxygen therapy coupled
with presentation of characteristic “chocolate brown” colour of
arterial blood[3,10,19–21]. Cyanotic presentation is typically
observed at methaemoglobin concentration > 15% of total
haemoglobin concentration[8,10]. Infants younger than 3 months
are more vulnerable to chemically induced-
methaemoglobinemia because the activities of their enzyme
systems that mitigate methaemoglobinemia do not reach that of
adult levels until after the age of 3 months[19,22–24]. Besides, fetal
haemoglobin is more easily oxidized to methaemoglobin than
adult haemoglobin[17].
4. Etiology and classiﬁcation
From patho-toxicological considerations, oxidation of hae-
moglobin to methaemoglobin arises from the activities of pro-
oxidants and reactive oxidants that are able to access the haem
iron moiety of haemoglobin molecule[8]. However, auto-
oxidation of oxyhaemoglobin does occur at the rate of z 3%
per day and is accelerated under low oxygen tension, especially
when haemoglobin is partially oxygenated[6]. The non-functional
oxyhaemoglobin derivative (Fe3+) forms a complex with su-
peroxide ion (O2
−), which subsequently dismutates to generate
H2O2[6,25,26]. These reactive oxygen species can ultimately
damage the globin chain and/or the haem group[6,26,27]. The
oxidation of haemoglobin to methaemoglobin can be
represented thus:
Fe2+ + O2/ Fe
3+ $ O2
−
The basic etiological factors of methaemoglobinemia are
deﬁcient or impaired activity of NADH-methaemoglobin
reductase (NADH-MR; EC 1.6.2.2)[28,29] and/or expression of
hereditary mutant haemoglobin as a result of structural
alterations in a or b chains that stabilize haemoglobin
molecule in the Fe3+ state – the methaemoglobinopathies or
haemoglobin M (HbM)[2,30]. Furthermore, inhibitors of NADH-
MR activity promote methaemoglobinemia. For instance,
in vitro studies indicated that decameric vanadate in concentra-
tions as low as 50 mmol/L strongly inhibited NADH-MR ac-
tivity, and thereby caused the oxidation of haemoglobin to
methaemoglobin[31].
The four classes of methaemoglobinemia are differentiated
from each other based on their clinical history, causative agents
and pattern of transmission, optical spectrum presentation ofblood specimen and level of erythrocyte NADH-MR activ-
ity[3,6,30,32]. Two major types of molecular/metabolic events
leading to the presentation of methaemoglobinemia have been
identiﬁed. One is the methaemoglobinemia related to absence
or impaired enzymatic reduction of erythrocyte
methaemoglobin, clinically referred to as hereditary or
autosomal recessive congenital methaemoglobinemia[28,29,33,34],
and is linked to over 40 mutations of CYB5R3 gene
(22q13.31-qter)[35–38]. The CYB5R3 gene provides instructions
for the biosynthesis of two NADH-MR isoforms: the soluble
form present in the erythrocyte and the membrane bound form
localized in the endoplasmic reticulum, mitochondria, nuclei,
peroxisomes and plasma membranes of somatic cells[38,39].
Hereditary enzymopenic methaemoglobinemia has been
classiﬁed and described elsewhere[30] and studies showed that
the mutant NADH-MR are less thermally stable than the wild
type[36].
The oxidant load responsible for methaemoglobin formation,
in the circumstance of enzymopenic methaemoglobinemia, is
derived from endogenous sources and exacerbated by exposure
to xenobiotics[13,30]. Impaired enzymatic reduction of oxidized
haemoglobin is associated with normal haemoglobin structure
but severely reduced erythrocyte NADH-MR activity is char-
acterized clinically by cyanosis and variable amount of hae-
moglobin in the Fe3+ state. Reports have revealed that certain
patients with rare hereditary methaemoglobinemia exhibit more
pervasive NADH-MR activity deﬁciency affecting multitude of
tissues, particularly the central nervous tissues, with attendant
varying degree of mental retardation and unexplained severe
encephalopathy associated with generalized dystonia in chil-
dren[17,30,34,37,38,40]. Likewise, a case study report according to Da-
Silva et al.,[30] noted that congenital deﬁciency of innate
erythrocyte NADH-MR activity is so rare that only a few
cases are documented in the medical literature around the world.
Acquired/toxic methaemoglobinemia occurs as a result of
increased generation of methaemoglobin at a rate greater than
the capacity of enzymatic and non-enzymatic reduction path-
ways to reduce the oxidized haemoglobin, promoted by presence
of one or combinations of exogenous oxidants such as nitrates[41–
43], sulfonamide and its derivatives[8,10,42], nitrobenzene[9,21,42],
chlorate[42], aniline and aniline derivatives[10,42]. Also
worthwhile to mention are: prilocaine, benzocaine[13,14,23,44],
acetylsalicylic acid[45] and phenacetin[39,45]. Additionally, other
methaemoglobinemia promoting agents, including
pharmaceuticals, are listed elsewhere[13,14,40].
Apart from reported incidences of chemically induced-
methaemoglobinemia, parasitic infections, notably, malarial
parasites have been established to provoke raised levels of
methaemoglobin in plasma, parasitized erythrocytes and isolated
parasites in vitro[11,46]. There are also reported cases of
methaemoglobinemia associated with sepsis in infants,
whereby attendant release of nitric oxide elicits the oxidation
of haemoglobin[17]. Furthermore, the presence of high load of
intestinal ﬂora in diarrhoea episode promotes high gastric pH
and the conversion of nitrate to nitrite in the gastrointestinal
tract, which in turn absorbs into systemic circulation, and
elicits the formation of methaemoglobin[17].
The second type of methaemoglobinemia is associated with
mutant haemoglobin molecules, clinically referred to as the
methaemoglobinopathies or HbM[2]. They are generally resistant
to enzymatic reduction[39,47], and exhibit high degree of
molecular stability[48]. Among the ﬁve types that have been
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proximal or distal histidine residue either in a or b chains of
haemoglobin. The tyrosine residue by virtue of its phenolic
ion forms a very tight complex with haem Fe3+ moiety, and
thereby confers great stability to haemoglobin in Fe3+ state
strongly favouring its formation. These new bond formed
between the substituted tyrosine residue and haem Fe3+ moiety
of a or b chains are strong enough so that molecular
instability is not a component of the methaemoglobinopathies.
The ﬁve types of methaemoglobinopathies, designated by
geographic names, include the two a-chain variant, HbMlwait
and HbMBoston and the three b-chain variants are HbMHydepark,
HbMsaskaton and HbMmilwaukee-1[39,48].
4.1. Nitrogenous compounds induced-methaemoglobinemia
Apart from the incidence of cancer, chronic diarrhoea, res-
piratory distress and cardiovascular diseases that are associated
with the exposure of human to nitrite, ingestion and assimilation
of nitrite and related compounds are the most likely causes of
toxic methaemoglobinemia in man and aquatic life[9,24,49–56].
Humans are often exposed to nitrite by intake of contaminated
meat, vegetables, fruits and water that arose from the use of
preservatives, fertilizers, including anhydrous ammonia, as
well as disposal of livestock or human natural organic wastes,
and domestic and industrial sewage into water bodies[19,50,57,58].
Consequent upon the ingestion of nitrate, it is reduced to
nitrite by bacteria in the buccal cavity and gastrointestinal tract
and subsequently converted back to nitrate in the blood
stream[57,59,60]. The process of converting nitrite to nitrate in the
blood requires extracellular NADH, which directly oxidizes
haemoglobin to methaemoglobin[59].
Studies showed that nitrogen-containing compounds are the
most encountered agent that induces toxic methaemoglobinemia
in experimental animals and human. For instance, the intragastric
administration of the 4-substituted aniline derivatives, particu-
larly, 3,7-bis-(4-triﬂuoromethylphenyl)-1,5,3,7-dioxadiazocane
to male Wistar rats at a dose of 0.12 mmol/kg body weight/day
for three consecutive days caused methaemoglobinemia[61]. Also,
experimentally induced acute nitrite intoxication episode
(9.3 mmol/L NO2
−
–N for 18 h) provoked methaemoglobinemia
in Siberian sturgeon (Acipenser baeri) yearlings[53]. In another
report, Coleman and Taylor[62], noted that incubation of
benzocaine with microsomes from human hepatocytes
produced methaemoglobin-forming metabolites. However, case
study report revealed that incidence of benzocaine-induced
methaemoglobinemia is rare during procedures of topical
anaesthesia[13]. In aquatic life, nitrite-induced meth-
aemoglobinemia in different ﬁsh species, which may compro-
mise the ﬁsh's performance in nitrogenous compound-
contaminated environment have been reported[51–54,56].
The impact of freezing temperatures on formation and sta-
bility of chemically-induced methaemoglobin have been
controversially discussed. Cryopreservation of human blood
samples showed that methaemoglobin concentration was
comparatively stable for 10 days but increased signiﬁcantly by
Day 20 in nitrite-treated samples[63]. On the contrary, freeze-
drying a solution of oxyhaemoglobin caused the formation of
substantial level of methaemoglobin that was more resistant to
reduction by sodium dithionite than methaemoglobin formed
chemically by the action of potassium ferricyanide on
oxyhaemoglobin[64].4.2. Diabetic methaemoglobinemia
Although NADH-diaphorase levels measured in diabetics
and non-diabetics did not signiﬁcantly differ, erythrocytes from
diabetic subjects were less sensitive to the effect of monoacetyl
dapsone hydroxylamine- and dapsone hydroxylamine-induced
methaemoglobin formation[65,66]. Further elaborate
investigations, in this regard, have corroborated these ﬁndings.
Nevertheless, erythrocytes from diabetic and non-diabetic sub-
jects exhibited differential sensitivity to nitrite, monoacetyl
dapsone hydroxylamine, 4-aminophenol and disulﬁram-induced
methaemoglobin formation in vitro, which was mediated by
glutathione depleting effect and variations in cytosolic anti-
oxidant systems of corresponding erythrocytes[67–70].
Accordingly, experimental antioxidant therapy of diabetic
volunteers attenuated oxidative stress induced-methaemoglobin
formation in vitro and also lowered haemoglobin glycation
in vivo[69]. Glycosylation of haemoglobin and protein molecules,
the so called advanced glycation end products, have been
implicated in the generation of reactive oxygen and nitrogen
species[68,71], and may exacerbate hyperoxidative stress-induced
methaemoglobinemia in diabetic subjects. A report by Cole-
man[72], noted that the progress to ameliorate hyperoxidative
stress in diabetic subjects following antioxidant
supplementation, in the presence of aromatic amine
hydroxylamines, 4-aminophenol and nitrite, can be monitored
by a measure of methaemoglobin generation in vitro. Therefore,
a dynamic process of methaemoglobin generation in erythrocyte
from diabetic subjects in vitro offers an opportunity to ascertain
therapeutic beneﬁts following corrective antioxidant therapy[68].
5. Regulation of erythrocyte methaemoglobin
formation
Since the prime function of the erythrocyte is to feed oxygen
to body tissues, very precise and delicate mechanisms for the
regulation of methaemoglobin formation are set up and main-
tained in the erythrocytes. These metabolic pathways ensure
normal physiologic equilibrium between erythrocyte haemo-
globin and methaemoglobin concentrations. The most important
mechanism of reducing methaemoglobin is dependent on
glucose metabolism for the supply of NADH and NADPH to
provide electrons and protons for the enzymatic reduction of
methaemoglobin[8,73]. Erythrocyte NADH-MR, which accounts
for 95% reduction of methaemoglobin[74], has been characterized
as NADH diaphorase or diaphorase[75], NADH-ferricyanide
reductase[29] and NADH-cytochrome b5 reductase[11,28]. NADH-
MR is a ﬂavin adenine dinucleotide containing enzyme
responsible for proton and electron transfer from NADH to
cytochrome b5. Deﬁciency of NADH-MR has long been pro-
posed to be the cause of hereditary methaemoglobinemia[38,47,73].
Another enzyme reduction mechanism referred to as
NADPH-methaemoglobin reductase or diaphorase account for
only 5% contribution to total erythrocyte reduction pathway of
methaemoglobin[47,76]. Ascorbic acid and methylene blue have
been found to be co-reductants in the presence of diaphorase
but not diaphorase[76]. Diaphorase II-mediated regulation of
methaemoglobin formation is probably activated following the
failure of diaphorase I system, as a result of overwhelming levels
of oxidizing substances[47]. Also, through relatively minor
auxiliary mechanisms such as direct chemical reduction by
low molecular weight antioxidants (LMWAs) such as ascorbic
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the erythrocytes are able to reduce oxidizing molecules and
free radicals that cause the generation of methaemoglobin.
Also, these mechanisms probably function following the
failure of the NADH- and NADPH-enzyme systems[20,77]. An
exhaustive report on methaemoglobin reduction pathways
using computer simulations of metabolic networks have been
described elsewhere[74].
6. Treatmentandmanagementofmethaemoglobinemia
There are various curative measures in the treatment of meth-
aemoglobinemia[3,78]. One is methylene blue administration (1–
2 mg/kg) as 1% solution over 5 min, which quickly relieves
cyanosis associated with methaemoglobinemia[9,13,14,17,30]. It has
been demonstrated that the addition of methylene blue could
cause an approximately 10-fold increase in erythrocyte oxygen
consumption, which was a reﬂection of increased cellular level of
NADPH generation and metabolism of glucose through the
pentose phosphate pathway[73,77]. In essence, methylene blue is
converted to leucomethylene blue in the presence of NADPH,
which results in non-enzymatic reduction of meth-
aemoglobin[16,39,40,79]. In cases where methylene blue was
contraindicated, ascorbic acid was often the next line of
alternative therapy, its slow beneﬁcial effect
notwithstanding[9,14,80]. It is worthwhile to note that glucose-6-
phosphate dehydrogenase deﬁcient individuals do no respond to
methylene blue therapy and rapid haemolysis may ensue
following treatment due to low tissue levels of NADPH[40,81]. In
extreme cases, the application of exchange transfusion can be
performed.
Using in-vitro diabetic model in the presence of oxidative
stress promoters, administration of LMWAs, notably, ascorbate
and dihydrolipoic acid, effectively ameliorated hydroxylamine-
mediated methaemoglobin formation[82,83]. Likewise, level of
monoacetyl dapsone hydroxylamine-mediated methaemoglobin
formation was lowered by oxidized a-lipoic acid in erythrocytes
from non-diabetic and diabetic subjects[84].
The presence of chloride ions in aquatic life prevented the
development of methaemoglobinemia following short-term
exposure to nitrate. Speciﬁcally, Matsche et al.[56], inferred that
chloride buffering in aquaculture systems lowered toxic effects
of nitrite accumulation. Their inference, which was based on
empirical observation in ﬁsh, noted that acclimation of 10-fold
higher chloride content than the control values prevented the
concentration of nitrite in plasma above environmental levels or
development of methaemoglobinemia, which was consistent
with the report of Wang et al.[55].
7. Conclusions
Methaemoglobinemia arising from structural and functional
defective haemoglobins – the methaemoglobinopathies are rare
disorders, whereas toxic methaemoglobinemia is more prevalent
in man and aquatic animals. The majority of the chemically
induced-methaemoglobinemias were outcome of the presence of
relatively high concentrations of oxidizing agents that over-
whelmed the protective cellular reductive capacity of NADH-
MR activity rather than inhibition of the enzyme. The control
of physiologic levels of methaemoglobin is intricately inter-
twined with glucose metabolism for the supply of NADH and
NADPH to provide electrons and protons for enzymaticreduction of methaemoglobin in concert with auxiliary antioxi-
dant systems. The management and amelioration of meth-
aemoglobinemia involves exchange transfusion in conjunction
with methylene blue administration. The use of LMWAs have
also exhibited appreciable efﬁcacy in the treatment and man-
agement of toxic methaemoglobinemia.
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